← All countries · Europe
94%
MCV1
2025 · WHO/UNICEF estimate
90%
DTP3
2025 · WHO/UNICEF estimate
90%
IPV complete
2025 · WHO/UNICEF estimate
90%
HepB3
2025 · WHO/UNICEF estimate
3
Measles cases
2025 reported
33
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 96%2004 · WHO/UNICEF estimate | — | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 90%2025 · WHO/UNICEF estimate | — | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 90%2025 · WHO/UNICEF estimate | — | A · strong | |
| IPV1First dose of inactivated polio vaccine | 90%2025 · WHO/UNICEF estimate | — | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 90%2025 · WHO/UNICEF estimate | — | D · poor | |
| MCV1First dose of measles-containing vaccine | 94%2025 · WHO/UNICEF estimate | — | A · strong | |
| MCV2Second dose of measles-containing vaccine | 88%2025 · WHO/UNICEF estimate | — | A · strong | |
| RCV1First dose of rubella-containing vaccine | 94%2025 · WHO/UNICEF estimate | — | B · good | |
| HepB3Third dose of hepatitis B vaccine | 90%2025 · WHO/UNICEF estimate | — | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 90%2025 · WHO/UNICEF estimate | — | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | no data |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 55%2025 · WHO/UNICEF estimate | — | A · strong | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 42%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 42%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 26%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 32025 | 1.4per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 332025 | 15.6per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 12025 | 0.5per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 12025 | 0.5per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02022 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 172025 | 8per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (80 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | Risk group(s) | Epidemiological indications |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M3 | General/routine | Children born after 1.10.2019 |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M5 | General/routine | Children born after 1.10.2019 |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M11-M18 | General/routine | Children born after 1.10.2019 |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Epidemiological indications, other occupational risk groups, travellers | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Travellers | Epidemiological indications, other occupational risk groups, travellers | |
| HEPA_HEPBHepatitis A, Hepatitis B (HepA-HepB) vaccine | 1 | Health workers | Immunocompromised persons, some healthcare workers, other occupational risk groups, epidemiologic indication, travellers | |
| HEPA_HEPBHepatitis A, Hepatitis B (HepA-HepB) vaccine | 1 | Risk group(s) | Immunocompromised persons, some healthcare workers, other occupational risk groups, epidemiologic indication, travellers | |
| HEPA_HEPBHepatitis A, Hepatitis B (HepA-HepB) vaccine | 1 | Travellers | Immunocompromised persons, some healthcare workers, other occupational risk groups, epidemiologic indication, travellers | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Epidemiological indication, Children with specific medical indications, travellers | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Travellers | Epidemiological indication, Children with specific medical indications, travellers | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers | Healthcare workers, epidemiological indication, immunocompromised persons, other occupational risk groups, other specific indications, travellers | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Healthcare workers, epidemiological indication, immunocompromised persons, other occupational risk groups, other specific indications, travellers | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Travellers | Healthcare workers, epidemiological indication, immunocompromised persons, other occupational risk groups, other specific indications, travellers | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | Y5 | General/routine | Children at school entrance (5-6 years old) who were vaccinated with DTaP-Hib-IPV + children in 2nd grade of elementary school |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | HepBBD only administered to newborns of HBsAG positive mothers, simultaneously with immunoglobulin against Hepatitis B |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | Y5 | General/routine | Children at school entrance (5-6 years old) who were vaccinated with DTaP-Hib-IPV + children in 2nd grade of elementary school |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | Y7 | General/routine | Children at school entrance (5-6 years old) who were vaccinated with DTaP-Hib-IPV + children in 2nd grade of elementary school |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Risk group(s) | Immunocompromised persons | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y11 | HPV administered to females and males | Females and males in the 6th grade of elementary school |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | Females and males in the 6th grade of elementary school |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons 65 years of age or more |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | Risk group(s) | Epidemiological indication, other occupational risk groups, travellers | |
| IPVIPV (Inactivated polio vaccine) | 1 | Travellers | Epidemiological indication, other occupational risk groups, travellers | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) | Epidemiological indication, Immunocompromised persons, other occupational risk groups, travellers | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Travellers | Epidemiological indication, Immunocompromised persons, other occupational risk groups, travellers | |
| MEN_BMeningococcal B vaccine | 1 | Risk group(s) | Immunocompromised persons, epidemiological indications, other occupational risk groups, travellers | |
| MEN_BMeningococcal B vaccine | 1 | Travellers | Immunocompromised persons, epidemiological indications, other occupational risk groups, travellers | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M11-M18 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Health workers | Epidemiological indication, healthcare workers, other occupational risk groups | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Risk group(s) | Epidemiological indication, healthcare workers, other occupational risk groups | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y5 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 1 | M11-M18 | General/routine | MMRV vaccination is optional; parents may also choose vaccination with MMR. |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | Y3 | General/routine | MMRV vaccination is optional; parents may also choose vaccination with MMR. |
| MPOXMpox (monkeypox) vaccine | 1 | Health workers | Epidemiological indication, some healthcare workers, other occupational risk groups, specific indications | |
| MPOXMpox (monkeypox) vaccine | 1 | Risk group(s) | Epidemiological indication, some healthcare workers, other occupational risk groups, specific indications | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Adults | Immunocompromised persons,older persons, persons with specific chronic conditions | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Risk group(s) | Immunocompromised persons,older persons, persons with specific chronic conditions | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Adults | Immunocompromised persons, older persons, persons with specific chronic conditions | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M3 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Risk group(s) | Immunocompromised persons, older persons, persons with specific chronic conditions | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M5 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M6 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 4 | M11-M18 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Adults | Immunocompromised persons, older persons, persons with specific chronic conditions | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Risk group(s) | Immunocompromised persons, older persons, persons with specific chronic conditions | |
| RABIESRabies vaccine | 1 | Risk group(s) | In case of injury by an animal suspected to have rabies, other occupational risk groups, travellers | |
| RABIESRabies vaccine | 1 | Travellers | In case of injury by an animal suspected to have rabies, other occupational risk groups, travellers | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Adults | Pregnant adults and adolescents (24-36 wk), older persons | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Pregnant adults and adolescents (24-36 wk), older persons | |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | Risk group(s) | Premature newborns, Children with specific medical indications | |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 1 | Y45-Y55 | Adults | Adults aged 45–55 years are eligible to receive the vaccine free of charge.. People in occupational groups are eligible to receive the vaccine at any age, with the cost covered by the employer. |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 1 | Y45-Y55 | Risk group(s) | Adults aged 45–55 years are eligible to receive the vaccine free of charge.. People in occupational groups are eligible to receive the vaccine at any age, with the cost covered by the employer. |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 2 | +M1-M3 | Adults | Adults aged 45–55 years are eligible to receive the vaccine free of charge.. People in occupational groups are eligible to receive the vaccine at any age, with the cost covered by the employer. |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 2 | +M1-M3 | Risk group(s) | Adults aged 45–55 years are eligible to receive the vaccine free of charge.. People in occupational groups are eligible to receive the vaccine at any age, with the cost covered by the employer. |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 3 | +M5-M12 | Adults | Adults aged 45–55 years are eligible to receive the vaccine free of charge.. People in occupational groups are eligible to receive the vaccine at any age, with the cost covered by the employer. |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 3 | +M5-M12 | Risk group(s) | Adults aged 45–55 years are eligible to receive the vaccine free of charge.. People in occupational groups are eligible to receive the vaccine at any age, with the cost covered by the employer. |
| TBE_PEDIATRICPediatric TBE (tick borne encephalitis) vaccine | 1 | Y1 | General/routine | Children who turn one year old in current year |
| TBE_PEDIATRICPediatric TBE (tick borne encephalitis) vaccine | 2 | +M1-M3 | General/routine | Children who turn one year old in current year |
| TBE_PEDIATRICPediatric TBE (tick borne encephalitis) vaccine | 3 | +M5-M12 | General/routine | Children who turn one year old in current year |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Adults | Pregnant adults and adolescents (24th week onward), specific healthcare workers, adults | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Health workers | Pregnant adults and adolescents (24th week onward), specific healthcare workers, adults | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant adults and adolescents (24th week onward), specific healthcare workers, adults | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 5 | Y7 | General/routine | Children in 2nd grade of elementary school and students in their 1st to 3rd year of high school. 5th and 6th dose for children/young adults who were vaccinated with DTaP-Hib-IPV. |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y16-Y18 | General/routine | Children in 2nd grade of elementary school and students in their 1st to 3rd year of high school. 5th and 6th dose for children/young adults who were vaccinated with DTaP-Hib-IPV. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Adults | In case of injury and recommended every 10 years for adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Risk group(s) | In case of injury and recommended every 10 years for adults | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Risk group(s) | Epidemiological indication, Travellers, other occupational risk groups | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Travellers | Epidemiological indication, Travellers, other occupational risk groups | |
| VARICELLAVaricella vaccine | 1 | Health workers | Immunocompromised persons, Medical and other health related students, Healthcare workers, epidemiological indication | |
| VARICELLAVaricella vaccine | 1 | Risk group(s) | Immunocompromised persons, Medical and other health related students, Healthcare workers, epidemiological indication | |
| YFYF (Yellow fever) vaccine | 1 | Travellers | Travellers | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Risk group(s) | Immunocompromised persons, persons with specific chronic conditions |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.